Danaher Corporation (DHR)
NYSE · Healthcare · Diagnostics & Research
$221.21+3.34%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $156B
- P/E (trailing)
- 39.4
- Forward P/E
- 23.8
- Dividend yield
- 0.7%
- 52-week range
- $160.93 – $242.80
- 52-week change
- +2.53%
- EPS (trailing)
- $5.61
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Oct 21, 2026
Fiscal year to Dec 2025
- Revenue
- $24.6B (+2.90%)
- Net income
- $3.6B
- Operating margin
- 19.1%
- Diluted EPS
- $5.05
- Free cash flow
- $5.3B
From the company’s annual report on SEC EDGAR.
About Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions.
Headquarters: Washington, United States · 58,000 employees · danaher.com